Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR

Jan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, Julia Mattlener, Jonathan Weiss, Fabian Franzen, Christian Becker, Kerstin Becker, Philipp Gödel, Marcel Schmiel, Jörn Meinel, Ruth Flümann, Florian Simon, H Christian Reinhardt, Peter Borchmann, Sven Borchmann, Hyatt Balke-Want, Gero Knittel, Bastian von Tresckow

European Journal of Haematology

Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma

Berit Müller-Meinhard, Nicole Seifert, Johanna Grund, Sarah Reinke, Fatih Yalcin, Helen Kaul, Sven Borchmann, Bastian von Tresckow, Peter Borchmann, Annette Plütschow, Julia Richter, Andreas Engert, Michael Altenbuchinger, Paul J Bröckelmann, Wolfram Klapper

Hemasphere, 2024

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Conrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, Jan-Michel Heger, Beatrice Casadei, Laura Beckmann, Ken Herrmann, Franziska J Dekorsy, Nadine Kutsch, Peter Borchmann, Stefano Fanti, Wolfgang G Kunz, Marion Subklewe, Carsten Kobe, Pier Luigi Zinzani, Matthias Stelljes, Katrin S Roth, Alexander Drzezga, Richard Noppeney, Kambiz Rahbar, H Christian Reinhardt, Bastian von Tresckow, Robert Seifert, Jörn C Albring, Viktoria Blumenberg, Andrea Farolfi, Sarah Flossdorf, Philipp Gödel, Christine Hanoun

European Journal of Nuclear Medicine and Molecular Imaging, 2024

Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy

Dennis A Eichenauer, Jan-Michel Heger, Isabel Kruschel, Nadine Kutsch, Philipp Gödel, Jorge Garcia Borrega, Ulf Schnetzke, Boris Böll, Marie Anne-Catherine Neumann, Cordula Gebel, Anne Pralong, Peter Borchmann, Raymond Voltz, Ulrich Wedding, Steffen T Simon

British Journal of Haematology, 2024

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Jan-Michel Heger, Julia Mattlener, Jessica Schneider, Philipp Gödel, Noëlle Sieg, Fabian Ullrich, Richard Ian Lewis, Teodora Bucaciuc-Mracica, Roland F. Schwarz, Daniel Rueß, Maximilian I Ruge, Manuel Montesinos-Rongen, Martina Deckert, Tobias Blau, Nadine Kutsch, Hyatt Balke-Want, Jonathan Weiss, Kerstin Becker, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann

Blood, 2024

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Jan-Michel Heger, Laman Mammadova, Julia Mattlener, Sophia Sobesky, Melita Cirillo, Janine Altmüller, Elisabeth Kirst, Sarah Reinke, Wolfram Klapper, Paul J Bröckelmann, Justin Ferdinandus, Helen Kaul, Gundolf Schneider, Jessica Schneider, Julia Katharina Schleifenbaum, Roland T Ullrich, Max Freihammer, Sabine Awerkiew, Mia Lohmann, Florian Klein, Peter Nürnberg, Michael Hallek, Davide Rossi, Christine Mauz-Körholz, Stefan Gattenlöhner, Andreas Bräuninger, Peter Borchmann, Bastian von Tresckow, Sven Borchmann

Journal of Clinical Oncology, 2024

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

Conrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, Jan-Michel Heger, Carsten Kobe, Nadine Kutsch, Peter Borchmann, Markus Dietlein, Ken Herrmann, Matthias Stelljes, Kambiz Rahbar, Georg Lenz, H Christian Reinhardt, Marcel Teichert, Richard Noppeney, Jörn C Albring, Robert Seifert, Bastian von Tresckow, Sarah Flossdorf, Christine Hanoun

Hemasphere, 2023

Clinical applications of circulating tumor DNA in Hodgkin lymphoma

Jan-Michel Heger, Justin Ferdinandus, Julia Mattlener, Sven Borchmann

Semin Hematol , 2023

Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy

Jiaqi Fan, Anne Adams, Noëlle Sieg, Jan-Michel Heger, Philipp Gödel, Nadine Kutsch, David Kaul, Marcel Teichert, Bastian von Tresckow, Veit Bücklein, Gretha Goesmann, Minglun Li, Nathalie Struve, Maike Trommer, Philipp Linde, Johannes Rosenbrock, Eren Celik, Olaf Penack, Martin Stuschke, Marion Subklewe, Claus Belka, Michael von Bergwelt-Baildon, Peter Borchmann, Simone Marnitz, Christian Baues

Radiother Oncol ., 2023

Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment

Esther E E Drees, Yvonne W S Jauw, Erik van Dijk, Sven Borchmann, Sandra A W M Verkuijlen, Phylicia Stathi, Nils J Groenewegen, Nathalie J Hijmering, Daniella R A I Berry, Eric J Meershoek, Danielle Hoogmoed, Anne Kwakman, Tessa J Molenaar, Dirk M Pegtel, Bauke Ylstra, Daphne de Jong, Josée M Zijlstra, Margaretha G M Roemer

Hemasphere, 2022

Coming of age: the evolving role of circulating tumor DNA in malignant lymphoma

Jan-Michel Heger, Sven Borchmann

Leuk Lymphoma, 2022

Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

Maria Cristina Pirosa, Sven Borchmann, Fabrice Jardin, Gianluca Gaidano, Davide Rossi

Hemasphere, 2022

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Asmae Gassa, Johannes Brägelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid, Marieke Nill, Jana Fassunke, Amy J Wisdom, Anik Compes, Birgit Gathof, Hakan Alakus, David Kirsch, Khosro Hekmat, Reinhard Büttner, H Christian Reinhardt, Michael Hallek, Roland T Ullrich

Journal for Immuno Therapy of Cancer, 2022

An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer

Sven Borchmann

bioRxiv, Cold Spring Harbor Laboratory, 2020, p. 773200

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, Maria Alejandra Garcia-Marquez, Sven Borchmann, Franziska Jochims, Michaela Kotrova, Karol Pal, Monika Brüggemann, Elena Hartmann, others

Blood, 2020

Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication

Darko Antic, Vladimir Otasevic, Sven Borchmann, Horst Muller, Vojin Vukovic, Vladislava Djurasinovic, Kristina Tomic, Biljana Mihaljevic, Grigoris Gerotziafas, Andreas Engert, Jawed Fareed

Blood, vol. 136, 2020 Oct 5, pp. 8-8

Liquid biopsy in lymphoma: Molecular methods and clinical applications.

Melita Cirillo, Alexander F.M. Craig, Sven Borchmann*, David M. Kurtz*, *co-corresponding author

Cancer Treatment Reviews, vol. 91, 2020 Aug 22

Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.

Paul J. Bröckelmann, Sven Borchmann, Peter Borchmann, Andreas Engert

Journal of Clinical Oncology, 2020 Aug 18

Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome.

Yasemin Goereci, Finja Schweitzer, Anton Wellstein, Steffi Silling, Sven Borchmann, Bastian von Tresckow, Ortwin Adams, Roland Martin, Mark Schlamann, Michael Schroeter, Gereon R. Fink, Mike P. Wattjes, Clemens Warnke

European Journal of Neurology, 2020 Jun 9

Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC.

Caroline Volz, Sara Breid, Carolin Selenz, Alina Zaplatina, Kristina Golfmann, Lydia Meder, Felix Dietlein, Sven Borchmann, Sampurna Chatterjee, Maike Siobal, Jakob Schöttle, Alexandra Florin, Mirjam Koker, Marieke Nill, Luka Ozretić, Niklas Uhlenbrock, Steven Smith, Reinhard Büttner, Hui Miao, Bingcheng Wang, H. Christian Reinhardt, Daniel Rauh, Michael Hallek, Amparo Acker-Palmer, Lukas C. Heukamp, Roland T. Ullrich

Cell Reports, vol. 31(4), 2020 Mar 28

An update on disease biomarkers for Hodgkin lymphoma.

Melita Cirillo, Sven Borchmann

Expert Review of Hematology, vol. 13(5), 2020 Mar 2, pp. 481-488

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment

Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Sven Borchmann, Ilske Oschlies, Antje Schnitter, Andreas Engert, Peter Borchmann, Wolfram Klapper

haematologica, vol. 104, Ferrata Storti Foundation, 2019, pp. e45

Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma

Sven Borchmann, Melita Cirillo, Helen Goergen, Lydia Meder, Stephanie Sasse, Stefanie Kreissl, Paul Jan Bröckelmann, Bastian von Tresckow, Michael Fuchs, Roland Tillmann Ullrich, Andreas Engert

Journal of Clinical Oncology, vol. 37(36), 2019 Sep 17, pp. 3528-3537

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.

Jesko Momotow, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Sven Borchmann, Bastian v. Tresckow, Carsten Kobe, Andreas Engert, Stephanie Sasse

HemaSphere, vol. 3(5), 2019 Aug 27

Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials.

S. Borchmann, H. Müller, I. Hude, M. Fuchs, P. Borchmann, A. Engert

Annals of Oncology, vol. 30(8), 2019 Jul 1, pp. 1329-1334

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.

Frits I. Mulder, Matteo Candeloro, Pieter W. Kamphuisen, Marcello Di Nisio, Patrick M. Bossuyt, Noori Guman, Kirsten Smit, Harry R. Büller, Nick van Es

Haematologica, vol. 104(6), 2019 May 1, pp. 1277-1287

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie L. Batlevi, Philip C. Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette N. Owens, M. Lia Palomba, Anas Younes, David J. Straus

Blood, vol. 133(20), 2019 Apr 16, pp. 2121-2129

Suicide in European Hodgkin Lymphoma Patients.

Austin I. Kim, Helen Goergen, Andreas Engert, Ann S. LaCasce, Louise S. Maranda, Bruce A. Barton, Sven Borchmann

HemaSphere, vol. 3(2), 2019 Jan 21

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

Sven Borchmann, Horst Müller, Heinz Haverkamp, Christian Baues, Jana Marková, Andreas Hüttmann, Axel Glunz, Michael Fuchs, Peter Borchmann, Andreas Engert

Leukemia, vol. 33(2), 2019 Jan 1, pp. 439-446

The translational science of hodgkin lymphoma

Melita Cirillo, Sarah Reinke, Wolfram Klapper, Sven Borchmann

British Journal of Haematology, vol. 184(1), 2019 1, pp. 30-44

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Ilske Oschlies, Antje Schnitter, Sven Borchmann, Andreas Engert, Peter Borchmann, Wolfram Klapper

Haematologica, vol. 104(1), 2019 1

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma

Sven Borchmann, Andreas Engert

Oncotarget, vol. 9, Impact Journals, LLC, 2018, p. 37462

Hodgkin lymphoma in elderly patients

Sven Borchmann, Andreas Engert, Boris Böll

Current opinion in oncology, vol. 30, LWW, 2018, pp. 308--316

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.

Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans A. Schlößer, Margarete Odenthal, Reinhard Buettner, Juergen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, H. Christian Reinhardt, Roland T. Ullrich

Cancer Research, vol. 78(15), 2018 Jul 1, pp. 4270-4281

Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.

Kristina Golfmann, Lydia Meder, Mirjam Koker, Caroline Volz, Sven Borchmann, Lars Tharun, Felix Dietlein, Florian Malchers, Alexandra Florin, Reinhard Büttner, Neal Rosen, Vanessa Rodrik-Outmezguine, Michael Hallek, Roland T Ullrich

Oncogene, vol. 37(42), 2018 Jun 3, pp. 5682-5693

Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Ida Hude, Stephanie Sasse, Paul J. Bröckelmann, Bastian von Tresckow, Jesko Momotow, Andreas Engert, Sven Borchmann

British Journal of Haematology, vol. 181(6), 2018 May 1, pp. 837-840

The genetics of Hodgkin lymphoma: an overview and clinical implications

Sven Borchmann, Andreas Engert

Current Opinion in Oncology, vol. 29, Wolters Kluwer, 2017, pp. 307--314

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude

Sven Borchmann, Horst Müller, Andreas Engert

Scientific reports, vol. 7, Nature Publishing Group, 2017, pp. 1--8

Novel agents in classical Hodgkin lymphoma

Sven Borchmann, Bastian von Tresckow

Leukemia \& lymphoma, vol. 58, Taylor \& Francis, 2017, pp. 2275--2286

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Stephanie Sasse, Paul J Bröckelmann, Helen Goergen, Annette Plütschow, Horst Müller, Stefanie Kreissl, Carolin Buerkle, Sven Borchmann, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert

Journal of Clinical Oncology, vol. 35(18), 2017 Mar 18, pp. 1999-2007

Current developments in the treatment of early-stage classical Hodgkin lymphoma.

Sven Borchmann, Bastian von Tresckow, Andreas Engert

Current Opinion in Oncology, vol. 28(5), 2016 Aug 1, pp. 377-383

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann

Blood, vol. 127(18), 2016 Apr 5, pp. 2189-2192

Multi-specific antibodies for cancer immunotherapy

Ron D* Jachimowicz, Sven* Borchmann, Achim Rothe, *contributed equally

BioDrugs, vol. 28, Springer International Publishing, 2014, pp. 331--343

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma

Achim Rothe*, Ron D. Jachimowicz*, Sven Borchmann*, Marie Madlener, Jörg Keßler, Katrin S. Reiners, Maike Sauer, Hinrich P. Hansen, Roland T. Ullrich, Sampurna Chatterjee, Peter Borchmann, Paul Yazaki, Thomas C. Koslowsky, Andreas Engert, Lukas C. Heukamp, Michael Hallek, Elke Pogge Von Strandmann, *contributed equally

International Journal of Cancer, vol. 134(12), 2014 May 15, pp. 2829-2840